X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary

By Megan Van Etten  |    April 13, 2023
At the direction of the U.S. Trade Representative, the U.S. International Trade Commission (USTIC) is investigating the impact of a proposed waiver of intellectual property (IP) protections for...   Read More

PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement

By Kevin Haninger  |    March 30, 2023
At the request of the U.S. Trade Representative, the U.S. International Trade Commission (USITC) is conducting an investigation and will issue an accompanying report concerning the TRIPS Agreement...   Read More

U.S. must address IP and market access barriers abroad to protect American innovation

By Ernest Kawka  |    January 31, 2023
PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine...   Read More

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

By Megan Van Etten  |    November 17, 2022
The United States has led the charge in the development of vaccines and treatments to combat COVID-19 thanks in large part to our robust innovation ecosystem, supported by intellectual property (IP)...   Read More

TRIPS waiver expansion risks public health

By Megan Van Etten  |    November 14, 2022
The Biden administration and other World Trade Organization members are considering expanding the harmful and unnecessary waiver of intellectual property (IP) protections under the Agreement on...   Read More

Expanding the WTO intellectual property waiver will hurt American jobs

By Megan Van Etten  |    November 9, 2022
The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was...   Read More

PhRMA submission to USTR calls for urgent defense of American innovation abroad

By Douglas Petersen  |    November 1, 2022
The United States leads the world in medicine research, development and manufacturing, and international trade delivers those medicines to patients around the globe. But trade barriers imposed in...   Read More

Partnerships are driving global COVID-19 treatment access

By Megan Van Etten  |    September 22, 2022
Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...   Read More

The dangers of expanding the TRIPS waiver

By Megan Van Etten  |    September 19, 2022
World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates